Analysts do see a lift to its sales, even as some of them are not factoring in sales beyond FY23 amid uncertainty over booster shots. The p...

Cadila Healthcare said it has signed an agreement to extend the tenure of the joint venture with a Bayer Group firm for a period of two mon...

Zydus Wellness had on Wednesday said it will acquire Heinz India.

The company had recently reported 53.26 per cent jump in consolidated net profit at Rs 590.8 crore.

The drug is used to treat symptoms of Benign Prostatic Hyperplasia (BPH) -- also called prostate gland enlargement.

Buy Cadila Healthcare Ltd. at a price target of Rs 415.0 and a stop loss at Rs 380 from entry point.

Buy Cadila Healthcare Ltd. at a price target of Rs 444.0 .

CLSA has upgraded Cadila Healthcare to ‘buy’ from ‘underperform’.

Shares of Cadila ended down 1.74 per cent at Rs 369.95 on the BSE on Friday.

The scrip touched its fresh 52-week high of Rs 558 on June 12, 2017 and its 52-week low of Rs 329.95 on December 26, 2016.

With the latest approvals from the USFDA, the group now has more than 140 approvals and has so far filed over 300 abbreviated new drug appl...

The group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said.

Shrugging off the disappointing numbers, the drug firm's scrip opened the day on a positive note and further jumped 9.48 per cent to Rs 379...

The company's board, which met today, decided to delist equity shares of the company from ASE, Cadila Healthcare said in a filing to the BS...

Cadila Health is a 'BUY' call with a target of Rs 1100 and a stop loss of Rs 1024.

In 2000, Zydus Cadila had created a strategic alliance with Ambalal Sarabhai Enterprises to integrate the animal healthcare business of bot...

Pharmaceutical firm Cadila Healthcare said its shareholders have approved the restructuring of its consumer products division as subsidiary...